Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6169MR)

This product GTTS-WQ6169MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6169MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11539MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ6412MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ708MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-623
GTTS-WQ1766MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ7588MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ10871MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ1163MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ9172MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW